Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up

被引:165
作者
Helgason, S [1 ]
Petursson, G
Gudmundsson, S
Sigurdsson, JA
机构
[1] Arbaer Hlth Care Ctr, IS-110 Reykjavik, Iceland
[2] Univ Iceland, Dept Family Med, IS-105 Reykjavik, Iceland
[3] Directorate Hlth, IS-150 Reykjavik, Iceland
基金
英国惠康基金;
关键词
D O I
10.1136/bmj.321.7264.794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the frequency, duration, and clinical importance of postherpetic neuralgia after a first episode of herpes tester. Design Prospective cohort study with long term follow up. Setting Primary health care in Iceland. Participants 421 patients with a first episode of herpes tester. Main outcome measures Age and sex distribution of patients with herpes tester, point prevalence or postherpetic neuralgia, and severity of pain at 1, 3, 6, and 12 months and up to 7.6 years after the outbreak of zoster. Results Among patients) younger than 60 years, the risk of postherpetic neuralgia three months after the start of the tester rash was 1.8% (95% confidence interval 0.59% to 4.18%) and pain was mild in all cases. In patients 60 years and older, the risk of postherpetic neuralgia increased but the pain was usually mild or moderate. After three months severe pain was recorded in two patients older than 60 years (1.7%, 2.14% to 6.15%). After 12 months no patient reported severe pain and 14 patients (3.3%) had mild or moderate pain. Seven of these became pain free within two to seven years, and five reported mild pain and one moderate pain after 7.6 years of follow up. Sex was not a predictor of postherpetic neuralgia. Possible immunomodulating comorbidity (such as malignancy, systemic steroid use, diabetes) was present in It patients. Conclusions The probability of longstanding pain of clinical importance after herpes tester is lo it in an unselected population of primary care patients essentially untreated with antiviral drugs.
引用
收藏
页码:794 / 796A
页数:4
相关论文
共 25 条
[1]   VALACICLOVIR COMPARED WITH ACYCLOVIR FOR IMPROVED THERAPY FOR HERPES-ZOSTER IN IMMUNOCOMPETENT ADULTS [J].
BEUTNER, KR ;
FRIEDMAN, DJ ;
FORSZPANIAK, C ;
ANDERSEN, PL ;
WOOD, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1546-1553
[2]   The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population [J].
Bowsher, D .
EUROPEAN JOURNAL OF PAIN-LONDON, 1999, 3 (04) :335-342
[3]  
Christensen P, 1985, Ugeskr Laeger, V147, P3401
[4]   A HIGH-RISK METHOD FOR STUDYING PSYCHOSOCIAL ANTECEDENTS OF CHRONIC PAIN - THE PROSPECTIVE INVESTIGATION OF HERPES-ZOSTER [J].
DWORKIN, RH ;
HARTSTEIN, G ;
ROSNER, HL ;
WALTHER, RR ;
SWEENEY, EW ;
BRAND, L .
JOURNAL OF ABNORMAL PSYCHOLOGY, 1992, 101 (01) :200-205
[5]   Assessment of pain in herpes zoster: Lessons learned from antiviral trials [J].
Dworkin, RH ;
Carrington, D ;
Cunningham, A ;
Kost, RG ;
Levin, MJ ;
McKendrick, MW ;
Oxman, MN ;
Rentier, B ;
Schmader, KE ;
Tappeiner, G ;
Wassilew, SW ;
Whitley, RJ .
ANTIVIRAL RESEARCH, 1997, 33 (02) :73-85
[6]  
GARDNER MJ, 1989, STAT CONFIDENCE
[7]  
GEBSKY V, 1992, SPIDA USERS MANUAL
[8]   ORAL ACYCLOVIR IN HERPES-ZOSTER OPHTHALMICUS [J].
HARDING, SP ;
PORTER, SM .
CURRENT EYE RESEARCH, 1991, 10 :177-182
[9]  
HAYENS B, 1998, EVIDENCE BASED MED, V3, P130
[10]  
HELGASON S, 1996, EUR J GEN PRACT, V2, P12, DOI DOI 10.3109/13814789609161651